Download now: Oil Price Outlook 2024

Protect Your Wealth and Freedom From Biden’s Vaccine Mandate

Jeff Siegel

Written By Jeff Siegel

Posted November 11, 2021

Late last week, Joe Biden’s vaccine mandate was denied by a U.S. appeals court.

The mandate, which would require workers at private companies with more than 100 employees to undergo weekly testing or vaccination, was found to have “grave statutory and constitutional” issues.

Now, I’m no constitutional scholar.  

I have no idea, based on precedent, whether or not the mandate could violate the Constitution.

But here’s what I do know…

Even if Biden were able to convince the courts that the federal government does have the right to mandate vaccines, the roadblocks and lawsuits that would follow would make it virtually impossible to enforce.  

Of course, this is always the problem with government: Choosing force over voluntary agreement never ends well.

Look, I get it. COVID-19 is very real and has made a lot of people very sick.

And the economic impact of this pandemic cannot be taken lightly.

But I’m not convinced that forcing people to get vaccinated is the best way to protect public health if we truly believe in the basic fundamentals of personal sovereignty, which dictate that only you have control over your own body and life. Your body, your mind, your choice. 

And honestly, the thought of violating personal sovereignty in this situation seems particularly absurd when you consider that very soon vaccines may not be necessary at all.

How Much Is a COVID-19 Cure Worth? 

Most people don’t spend a lot of time sifting through medical journals in their spare time.

But I do, because quite frankly I love this stuff.

I love reading about new medical innovations and technologies that will allow us all to live longer, healthier lives. It’s absolutely fascinating to me. 

Last week, while reading about new treatment developments for COVID-19, I came across a study conducted by the International Journal of Infectious Diseases, where researchers discovered what some are now calling a cure for COVID, using a powerful, all-natural immunity booster called “Alpha-2B.”

Until recently, I had never even heard of Alpha-2B, but at the beginning of the pandemic in a first-of-its-kind study, 77 COVID patients were given this Alpha-2B via a special nasal spray.

The result?

All 77 patients fully recovered — with not a single one getting severely ill.

That’s a 100% success rate, which is virtually unheard of with any other treatment that’s been brought to market.

What makes this particularly exciting, though, is that the U.S. National Library of Medicine found that it actually stops the virus from spreading, which means it can stop an outbreak before it even has a chance to begin.

This is truly game-changing biotech, and it works by essentially telling your immune system to produce more of a specific type of protein that fights off the virus.

It’s basically your own personal bodyguard against the world’s most lethal viruses.

As Dr. Angela Rasmussen, a virologist and research scientist at Columbia University, explains it, Alpha-2B is like a fire alarm and sprinkler system all in one.

Not only does it keep you from getting sick but if you’re already showing symptoms of COVID, it stops the virus dead in its tracks.

It’s funny, but while politicians and lawyers are debating the constitutionality of vaccine mandates, there’s a company currently running clinical trials on Alpha-2B, with some insiders suggesting that the FDA could actually end up fast-tracking this treatment.

Because you see, not only can Alpha-2B successfully combat COVID, but it can also protect against other serious viruses, such as hepatitis B and C, Ebola, dengue fever, West Nile virus, and even influenza.

As a person who just wants to see these viruses eradicated so we can save millions of lives, I find this incredibly exciting. And as an investor, you can imagine just how bullish I am on this thing too.

Think about it for a moment…

A simple nasal spray (no needles or series of vaccine boosters) with the ability to put an end to not just COVID but dozens of other viruses that have plagued mankind for years.

This is a game-changer of epic proportions, and unless you hate money, I would encourage you to learn more about the company that’s developed this nasal spray — because it’s publicly traded and you can buy shares of it right now. 

It’s not Merck, Pfizer, or Johnson & Johnson. It’s actually a very small biotech player that, in my opinion, is on the cusp of getting acquired by one of these biotech giants for a huge premium. Because let’s face it: A cure for COVID-19, as well as dozens of other deadly viruses, will be worth billions. 

Of course, you want to get in before that happens, which is why I’m including this investment note in today’s update so you can learn more about Alpha-2B, what it can do, and the name and ticker symbol of the company that created it.

While I don’t know how this federal mandate issue is going to play out, I do know that any company offering what is essentially a cure for COVID is a company I want to own.  

You should too.

Get in on this action for yourself.

To a new way of life and a new generation of wealth…

Jeff Siegel Signature

Jeff Siegel

follow basicCheck us out on YouTube!

follow basic@JeffSiegel on Twitter

Jeff is the founder and managing editor of Green Chip Stocks. For more on Jeff, go to his editor’s page.

Want to hear more from Jeff? Sign up to receive emails directly from him ranging from market commentaries to opportunities that he has his eye on. 

Angel Pub Investor Club Discord - Chat Now

Jeff Siegel Premium


Hydrogen Fuel Cells: The Downfall of Tesla?

Lithium has been the front-runner in the battery technology market for years, but that is all coming to an end. Elon Musk is against them, but Jeff Bezos is investing heavily in them. Hydrogen Fuel Cells will turn the battery market upside down and we've discovered a tiny company that is going to make it happen...

Sign up to receive your free report. After signing up, you'll begin receiving the Energy and Capital e-letter daily.